HoldsUp

Dr. Ford Brewer MD MPH · 2026-04-23 · Ford Brewer (host), Jesus Vega

The Real Reason Statins Are Overprescribed

32 research-tied claims examined: 3 contradicted 3 overstated 4 context 18 supported 4 unverified

3

Overstated

0:28:15Ford Brewer (host)overstatedmoderate

Sleep studies show that experiencing a single bad night of sleep measurably increases insulin resistance over the subsequent 48 to 72 hours.

"Sleep studies have been done which demonstrate very clearly that you can go in, have a bad night of sleep as measured by the sleep study machines, but still you don't notice it. You think you did okay; the next 48 to 72 hours your insulin resistance has increased." (said at 0:28:15)

Clinical studies confirm that a single night of partial sleep restriction (e.g., 4 hours of sleep) significantly increases peripheral and hepatic insulin resistance on the following morning in both healthy individuals and patients with type 1 diabetes. However, the claim overstates the duration of this effect by asserting that insulin resistance remains elevated for 48 to 72 hours following a single night of poor sleep. Standard physiological measurements demonstrate acute insulin resistance immediately following the sleep-restricted night, but published experimental protocols evaluate acute metabolic changes (such as hyperinsulinemic euglycemic clamp studies conducted the morning after) rather than sustained metabolic impairment lasting 2 to 3 days from a single isolated night of poor sleep.

0:51:20Ford Brewer (host)overstatedmoderate

Pitavastatin is the one statin that does not increase the risk of developing type 2 diabetes.

"The one statin that we know of that really doesn't do that is the one that still hasn't lost its um uh patent yet and is uh contributing an outsized share of those that billion dollars, those several billion dollars in costs uh in 2023: pitavastatin, or Livalo." (said at 0:51:20)

The host claims that pitavastatin is 'the one statin' that does not increase the risk of developing type 2 diabetes. Meta-analyses of randomized trials and observational cohorts confirm that pitavastatin does not adversely affect glucose metabolism or increase new-onset diabetes risk compared with placebo or active controls, and presents a lower risk than atorvastatin or rosuvastatin. However, framing pitavastatin as uniquely 'the one statin' with this property is overstated: other statins, particularly pravastatin, have also been shown in meta-analyses to be associated with little to no increased risk of new-onset diabetes compared to placebo.

0:53:44Jesus Vegaoverstatedhigh

People with full-blown type 2 diabetes have a 5 to 8 times increased risk of cardiovascular disease compared to individuals with high cholesterol alone.

"And especially with that people with full-blown diabetes who is well known they have I believe it's 5 to 8 times increased risk of heart disease compared even with people with high cholesterol. Which is massive." (said at 0:53:44)

Large prospective cohort analyses demonstrate that diabetes increases the risk of cardiovascular disease approximately 2-fold compared to individuals without diabetes, not 5- to 8-fold. In a collaborative individual-participant meta-analysis of 102 prospective studies encompassing 698,782 participants by the Emerging Risk Factors Collaboration, baseline diabetes was associated with an adjusted hazard ratio of 2.00 (95% CI: 1.83–2.19) for coronary heart disease and 2.27 (95% CI: 1.95–2.65) for ischemic stroke. Because hypercholesterolemia is itself an established cardiovascular risk factor, the relative risk of cardiovascular disease in people with diabetes compared specifically to people with high cholesterol alone is even lower than 2-fold, directly contradicting the claimed 5- to 8-fold increase.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.